RE:RE:RE:RE:Pfizer pivots to 'externalization" of rare disease programs ONCY also reprted that : "In the GOBLET trial's pancreatic cancer cohort ... objective responses suggested pelareorep's clinically demonstrated synergy with checkpoint inhibition in breast cancer extends into additional difficult-to-treat indications. Together, these findings further position pelareorep as an immune platform molecule that can enhance the efficacy of a variety of drug classes to improve treatment paradigms across a range of indications."
Then in November ONCY reported updated results from the phase 1/2 GOBLET study's first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort were treated with the combination of pelareorep, Roche's anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel. This PDAC cohort reported a 69% Objective Response Rate (ORR) and an 82% Clinical Benefit Rate (CBR) with 13 patients experiencing 1 complete response, 8 partial responses and 2 stable disease confirmations .... results that no other combination of I/O agents have achieved.